Details

Autor(en) / Beteiligte

• Parekh, Deevyashali
• Lin, Howard
• Batajoo, Akanksha
• Peckham‐Gregory, Erin
• Karri, Vivekanudeep
• Stanton, Whitney
• Scull, Brooks
• Fleishmann, Ryan
• El‐Mallawany, Nader
• Eckstein, Olive S.
• Prudowsky, Zachary D.
• Gulati, Nitya
• Agrusa, Jennifer E.
• Ahmed, Asra Z.
• Chu, Roland
• Dietz, Matthew S.
• Goldman, Stanton C.
• Hogarty, Michael D.
• Imran, Hamayun
• Intzes, Stefanos
• Kim, Jenny M.
• Kopp, Lisa M.
• Levy, Carolyn Fein
• Neff, Philip
• Pillai, Pallavi M.
• Sisk, Bryan A.
• Schiff, Deborah E.
• Trobaugh‐Lotrario, Angela D.
• Walkovich, Kelly
• McClain, Kenneth L.
• Allen, Carl E.

Titel

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis

Ist Teil von

• British journal of haematology, 2024-05, Vol.204 (5), p.1888-1893

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• Summary Over 50% of patients with systemic LCH are not cured with front‐line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.6%, higher in children (93.8%) than adults (83.3%). BRAFV600E+ variant allele frequency in peripheral blood is correlated with clinical responses. Prospective multicentre trials are warranted to determine optimal dosing, long‐term efficacy, late toxicities, relative cost and patient‐reported outcomes of clofarabine compared to alternative LCH salvage therapy strategies.